MacroGenics, Inc. — Q2 2016 Form 10-Q
Reporting period: Three and six months ended June 30, 2016. MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies. It reported no product sales and relies on collaborations, grants, and financing to fund operations.
Financial performance and position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Total revenue | $80.7m | $6.7m | $83.5m | $78.0m |
| Operating expenses | $40.6m | $28.0m | $74.1m | $54.2m |
| Operating income (loss) | $40.1m | $(21.3)m | $9.5m | $23.8m |
| Net income (loss) | $40.5m | $(21.4)m | $10.1m | $23.8m |
| Diluted EPS | $1.12 | $(0.71) | $0.28 | $0.75 |
- Q2 operating margin was approximately 49.7%; six-month operating margin was approximately 11.3%, calculated from reported revenue and operating income.
- Research and development expense was $33.3m in Q2 and $60.7m for the half-year, up 47% and 38%, respectively. General and administrative expense was $7.2m and $13.4m, up 35% and 34%.
- Six-month operating cash flow was negative $65.1m, versus positive $18.1m in 2015. Investing cash flow was negative $69.1m; financing cash flow was positive $0.4m. Cash and cash equivalents fell $133.9m to $62.3m.
- At June 30, cash, cash equivalents, and marketable securities totaled $265.6m, including $203.4m of marketable securities. Accounts receivable was $78.4m; the filing attributes the increase chiefly to a $75.0m Janssen payment recognized before it was collected. Janssen paid it in July.
- Total liabilities were $38.9m and stockholders’ equity was $330.0m. The balance sheet reports no borrowings or debt. Management cited cash, securities, and anticipated collaboration payments as sufficient to fund operations into 2018, assuming programs advance as planned.
Material changes and notable items
- Q2 collaboration revenue included $75.0m recognized under the new Janssen MGD015 agreement and a $2.0m Pfizer milestone. Q2 total revenue rose to $80.7m from $6.7m. The MGD015 upfront payment was received after quarter-end, contributing to the receivable and negative operating cash flow.
- For the first half, revenue increased 7% to $83.5m. The prior-year period included $62.3m recognized under the Janssen MGD011 agreement; 2016 included the MGD015 revenue instead. Government-agreement revenue rose to $3.1m, primarily with higher NIAID contract activity.
- Higher R&D spending reflected expanded immune-checkpoint programs, initiation of a Phase 1 trial of MGD009, and combination trials involving enoblituzumab. A $1.3m lease-exit-liability adjustment reduced Q2 R&D expense; the company expects approximately $1.3m in sublease payments through February 2018.
- Janssen’s MGD015 agreement provides up to $665m in development, regulatory, and sales milestones, plus potential royalties. These future amounts depend on successful development and commercialization and are not guaranteed.
Outlook, risks, and contingencies
No formal revenue or earnings guidance is provided. Management expects operating expenses to increase as clinical trials and preclinical work continue. The stated runway into 2018 depends on anticipated collaboration payments and programs progressing as planned; additional milestone and reimbursement receipts are uncertain. Key risks include clinical and regulatory outcomes, development costs, collaboration and funding dependence, competition, and the possibility that candidates never obtain approval or generate product revenue. The filing also describes potential contingent payments connected to the Raven acquisition, including a $5.0m payment if a qualifying Phase 2 trial begins by July 15, 2018; no additional contingent consideration was recorded in the reported periods.
Important facts for investors to verify
- Collection and timing of the $75.0m Janssen MGD015 payment and the other large receivable balance.
- Whether collaboration programs progress sufficiently to support management’s stated runway into 2018.
- Clinical-trial progress, spending plans, and the potential for additional development milestones or collaboration funding.
- Drivers of the sharp Q2 profit improvement, particularly the non-recurring nature and timing of collaboration revenue.
- Risk-factor disclosures in the company’s 2015 Form 10-K; this filing refers investors to those disclosures.